Epidemiology and Meningococcal Serogroup Distribution in the United States

Abstract

Get full access to this article

View all access options for this article.

References

AAP. Prevention and control of meningococcal disease: recommendations for use of meningococcal vaccines in pediatric patients. Pediatrics. Aug 2005 ;116(2):496-505.

Bilukha OO , Rosenstein N. CDC. Prevention and control of meningococcal disease. Recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep. May 27 2005;54(RR-7):1-21.

CDC. The Pink Book: Epidemiology and Prevention of Vaccine Preventable Diseases. 11th edition ed; 2009.

AAP. Meningococcal disease prevention and control strategies for practice-based physicians (Addendum: recommendations for college students). Committee on Infectious Diseases. Pediatrics. Dec 2000;106(6):1500-1504.

Cohn AC , MacNeil JR , Harrison LH , et al. Changes in Neisseria meningitidis disease epidemiology in the United States, 1998-2007: implications for prevention of meningococcal disease . Clin Infect Dis. Jan 15 2010;50(2): 184-191.

Hall-Baker PA , Nieves E. , Jajosky RA , et al. Summary of notifiable diseases-United States, 2007. MMWR Morb Mortal Wkly Rep. July 9 2009;56(53):1-100.

CDC. Active Bacterial Core Surveillance (ABCs) 1997-2008 surveillance reports. http://www.cdc.gov/ncidod/dbmd/abcs/. Accessed November 18, 2009.

National Foundation for Infectious Diseases. The changing epidemiology of meningococcal disease among US children, adolescents and young adults. 1-15. Available at: http://www.nfid.org/pdf/meningitis/FINALChanging_Epidemiology_of_Meningococcal_Disease.pdf .

Nassif X. , Pujol C. , Morand P. , Eugene E. Interactions of pathogenic Neisseria with host cells. Is it possible to assemble the puzzle? Mol Microbiol. Jun 1999;32(6):1124-1132.

10.

Rosenstein NE , Perkins BA , Stephens DS , et al. The changing epidemiology of meningococcal disease in the United States, 1992-1996. J Infect Dis. Dec 1999;180(6):1894-1901.

11.

Kirsch EA , Barton RP , Kitchen L. , Giroir BP Pathophysiology, treatment and outcome of meningococcemia: a review and recent experience. Pediatr Infect Dis J. Nov 1996 ;15(11):967-978; quiz 979.

12.

Harrison LH Prospects for vaccine prevention of meningococcal infection. Clin Microbiol Rev. Jan 2006;19(1):142-164.

13.

Harrison LH , Pass MA , Mendelsohn AB , et al. Invasive meningococcal disease in adolescents and young adults . JAMA. Aug 8 2001;286(6):694-699.

14.

CDC. Meeting of The Advisory Committee on Immunization Practices (ACIP). Epidemiology of Meningococcal Disease in Infants and Young Children; October 21-22, 2009; Atlanta, GA.

15.

Edwards MS , Baker CJ Complications and sequelae of meningococcal infections in children . J Pediatr. Oct 1981;99(4):540-545.

16.

Greenfield S. , Sheehe PR , Feldman HA Meningococcal carriage in a population of "normal" families. J Infect Dis. Jan 1971;123(1):67-73.

17.

Caugant DA , Hoiby EA , Magnus P. , et al. Asymptomatic carriage of Neisseria meningitidis in a randomly sampled population. J Clin Microbiol. Feb 1994;32(2):323-330.

18.

Cartwright KA , Stuart JM , Jones DM , Noah ND The Stonehouse survey: nasopharyngeal carriage of meningococci and Neisseria lactamica. Epidemiol Infect. Dec 1987;99(3):591-601.

19.

Schmidt MA Implications of Broad-Spectrum Antibiotic Use Among Young Children on the Epidemiology of Invasive Meningococcal Disease. Interscience Conference on Antimicrobial Agents and Chemotherapy/Infectious Diseases Society of America. Washington D.C.; 2008.

20.

Rosenstein NE , Perkins BA , Stephens DS , Popovic T. , Hughes JM Meningococcal disease. N Engl J Med. May 3 2001;344(18):1378-1388.

21.

Claus H. , Maiden MC , Maag R. , Frosch M. , Vogel U. Many carried meningococci lack the genes required for capsule synthesis and transport. Microbiology. Jun 2002;148(Pt 6):1813-1819.

22.

Hoang LM , Thomas E. , Tyler S. , et al. Rapid and fatal meningococcal disease due to a strain of Neisseria meningitidis containing the capsule null locus. Clin Infect Dis. Mar 1 2005;40(5):e38-42.

23.

Vogel U. , Claus H. , von Muller L. , et al. Bacteremia in an immunocompromised patient caused by a commensal Neisseria meningitidis strain harboring the capsule null locus (cnl). J Clin Microbiol. Jul 2004;42(7):2898-2901.

24.

Goldschneider I. , Gotschlich EC , Artenstein MS Human immunity to the meningococcus. II. Development of natural immunity. J Exp Med. Jun 1 1969 ;129(6):1327-1348.

25.

Cohn A. , Mayer L. , Zell E. , et al. Burden of Meningococcal Disease in Infants, United States 1997-2006. Interscience Conference on Antimicrobial Agents and Chemotherapy/ Infectious Diseases Society of America. Washington D.C.; 2008.

26.

Jackson LA , Wenger JD Laboratory-based surveillance for meningococcal disease in selected areas, United States, 1989-1991. MMWR CDC Surveill Summ. Jun 4 1993;42(2):21-30.

27.

Filice GA , Englender SJ , Jacobson JA , et al. Group A meningococcal disease in skid rows: epidemiology and implications for control. Am J Public Health. Mar 1984;74(3):253-254.

28.

CDC. Update: assessment of risk for meningococcal disease associated with the Hajj 2001. MMWR Morb Mortal Wkly Rep. Mar 30 2001;50(12):221-222.

29.

Harrison LH , Jolley KA , Shutt KA , et al. Antigenic shift and increased incidence of meningococcal disease. J Infect Dis. May 1 2006;193(9):1266-1274.

30.

Swartley JS , Marfin AA , Edupuganti S. , et al. Capsule switching of Neisseria meningitidis . Proc Natl Acad Sci U S A. Jan 7 1997;94(1):271-276.

31.

Tsang RS , Law DK , Tyler SD , et al. Potential capsule switching from serogroup Y to B: The characterization of three such Neisseria meningitidis isolates causing invasive meningococcal disease in Canada. Can J Infect Dis Med Microbiol. May 2005;16(3):171-174.

32.

Claus H. , Vogel U. , Muhlenhoff M. , Gerardy-Schahn R. , Frosch M. Molecular divergence of the sia locus in different serogroups of Neisseria meningitidis expressing polysialic acid capsules. Mol Gen Genet. Dec 1997;257(1):28-34.

33.

Frosch M. , Weisgerber C. , Meyer TF Molecular characterization and expression in Escherichia coli of the gene complex encoding the polysaccharide capsule of Neisseria meningitidis group B. Proc Natl Acad Sci U S A. Mar 1989 ;86(5):1669-1673.

34.

Simoes MJ , Cunha M. , Almeida F. , Furtado C. , Brum L. Molecular surveillance of Neisseria meningitidis capsular switching in Portugal, 2002-2006. Epidemiol Infect. Jul 31 2008:1-5.

35.

Balmer P. , Borrow R. , Miller E. Impact of meningococcal C conjugate vaccine in the UK. J Med Microbiol. Sep 2002;51(9):717-722.

36.

Trotter CL , Ramsay ME , Gray S. , Fox A. , Kaczmarski E. No evidence for capsule replacement following mass immunisation with meningococcal serogroup C conjugate vaccines in England and Wales. Lancet Infect Dis. Oct 2006;6(10):616-617; author reply 617-618.

37.

Borrow R. , Goldblatt D. , Andrews N. , et al. Antibody persistence and immunological memory at age 4 years after meningococcal group C conjugate vaccination in children in the United Kingdom. J Infect Dis. 2002;186:1353-1357.

38.

Centers for Disease Control and Prevention (CDC). Report from the Advisory Committee on Immunization Practices (ACIP): decision not to recommend routine vaccination of all children aged 2-10 years with quadrivalent meningococcal conjugate vaccine (MCV4). MMWR Morb Mortal Wkly Rep. 2008;57:10-13.

39.

Pichichero M. , Casey J. , Blatter M. , et al. Comparative trial of the safety and immunogenicity of quadrivalent (A, C, Y, W-135) meningococcal polysaccharide-diphtheria conjugate vaccine versus quadrivalent polysaccharide vaccine in two-to ten-year-old children. Pediatr Infect Dis J. 2005;24:57-62.

40.

Centers for Disease Control and Prevention (CDC). Recommendation from the Advisory Committee on Immunization Practices (ACIP) for use of quadrivalent meningococcal conjugate vaccine (MCV4) in children aged 2-10 years at increased risk for invasive meningococcal disease . MMWR Morb Mortal Wkly Rep. 2007;56:1265-1266.

41.

Centers for Disease Control and Prevention (CDC). Revised recommendations of the Advisory Committee on Immunization Practices to vaccinate all persons aged 11-18 years with meningococcal conjugate vaccine. MMWR Morb Mortal Wkly Rep. 2007;56:794-795.

42.

Bruce MG , Rosenstein NE , Capparella JM , et al. Risk factors for meningococcal disease in college students. JAMA. 2001;286:688-693.

43.

Harrison LH , Dwyer DM , Maples CT , Billmann L. Risk of meningococcal infection in college students. JAMA. 1999;281:1906-1910.

44.

Centers for Disease Control and Prevention (CDC). Laboratory-acquired meningococcal disease: United States, 2000. MMWR Morb Mortal Wkly Rep. 2002 ;51:141-144.

45.

Brundage JF , Zollinger WD Evolution of Meningococcal Disease Epidemiology in the U.S. Army. Vol 1. Boca Raton, FL: CRC Press; 1987.

46.

Riedo FX , Plikaytis BD , Broome CV Epidemiology and prevention of meningococcal disease. Pediatr Infect Dis J. 1995;14:643-657.

47.

Fijen CA , Kuijper EJ , Drogari-Apiranthitou M. , et al. Protection against meningococcal serogroup ACYW disease in complement-deficient individuals vaccinated with the tetravalent meningococcal capsular polysaccharide vaccine. Clin Exp Immunol. 1998;114:362-369.

48.

Figueroa JE , Densen P. Infectious diseases associated with complement deficiencies. Clin Microbiol Rev. 1991;4: 359-395.

49.

Platonov AE , Vershinina IV , Kuijper EJ , Borrow R. , Kayhty H. Long term effects of vaccination of patients deficient in a late complement component with a tetravalent meningococcal polysaccharide vaccine. Vaccine . 2003; 21:4437-4447.

50.

Francke EL , Neu HC Postsplenectomy infection. Surg Clin North Am. 1981;61:135-155.

51.

Miller J. , Marshall G. , Marchant C. , et al. Immunity to an investigational H. influenzae type-b N. meningitidis serogroups C & Y conjugate vaccine measured in a serum bactericidal activity in an assay using human complement. Poster presented at: 48th Interscience Conference on Antimicrobial Agents and Chemotherapy/Infectious Diseases Society of America; October 25-28, 2008; Washington, DC.

52.

Miller J. , Friedland LR , de La Bourdonnaye G. , de Vleeschauwer I. , Boutriau D. Immunogenicity and safety of an investigational combined Haemophilus influenzae type b and Neisseria meningitidis serogroups C and Y conjugate vaccine in healthy infants compared to licensed controls. Poster presented at: 2007 Pediatric Academic Societies’ Annual Meeting ; May 5-8, 2007; Toronto, Ontario, Canada.

53.

Nolan T. , Marshall H. , Richmond P. , et al. Immunogenicity and safety of a combined Haemophilus influenzae type b-Neisseria meningitidis serogroups C and Y-tetanus toxoid conjugate (HibCY) candidate vaccine. Poster presented at: 45th Annual Meeting of the Infectious Diseases Society of America; October 4-7, 2007; San Diego, CA.

54.

Nolan T. , Lambert S. , Roberton D. , et al. A novel combined Haemophilus influenzae type b-Neisseria meningitidis serogroups C and Y-tetanus-toxoid conjugate vaccine is immunogenic and induces immune memory when co-administered with DTPa-HBV-IPV and conjugate pneumococcal vaccines in infants. Vaccine. 2007;25:8487-8499.

55.

Snape MD , Perrett KP , Ford KJ , et al. Immunogenicity of a tetravalent meningococcal glycoconjugate vaccine in infants: a randomized controlled trial. JAMA. 2008; 299:173-184.

56.

Keyserling H. , Pina M. , Hou V. , Bassily E. , Reinhardt A. Immunogenicity of a quadrivalent meningococcal polysaccharide diphtheria toxoid conjugate vaccine against serogroups A, C, Y, and W-135 (MCV4) in 9 to 15-month olds . Paper presented at: 44th Annual Meeting of the Infectious Diseases Society of America; October 12-15, 2006; Toronto, Ontario, Canada.